Patients of gastro-esophageal reflux symptoms
Conditions
Interventions
Vonoprazan 20mg oral once a day in the evning, 4weeks
Esomeprazole 20mg oral once a day in the evning, 4 weeks
Sponsors
Hattori clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: i) The patients who have freely provided written informed consent for the participation of this study after the oral or written sufficient explanation. ii) The patients with heartburn and/or acid reflux during 2-3days/week or 4-7days/week in GerdQ.
Exclusion criteria
Exclusion criteria: i) The patients with warning signs such as vomiting, gastrointestinal bleeding and sudden weight loss. ii) The patients with confirmed or suspected malignant diseases. iii) The patients with a history of gastrointestinal resection of vagotomy. iv) The patients with a history of irritable bowel syndrome. v) The patients whose participation in this study would be contraindicated due to complications such as serious heaptic, renal or heart disease. vi) The Pregnant patients or possibly pregnant patients. vii) The patients prohibited the participant of this study by their attending physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The clinical improvement of GERD symptoms (heartburn, acid reflux) evaluated using self-assessment interview sheet, GerdQ, 4 weeks after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| i) The early efficacy of medication, on 1,3,7 day after treatment. ii) The incidence of side effects. | — |
Countries
Japan
Contacts
Public ContactKouichi Sakurai
Hattori clinic Hattori clinic
Outcome results
None listed